Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD.

[1]  T. van der Poll,et al.  Increased levels of sTNF receptors following OKT3 treatment. , 1994, Transplantation Proceedings.

[2]  D. Zemel,et al.  Interleukin-8 during peritonitis in patients treated with CAPD; an in-vivo model of acute inflammation. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  I. T. Ten Berge,et al.  Relationship of TNF-alpha, interleukin-6, and prostaglandins to peritoneal permeability for macromolecules during longitudinal follow-up of peritonitis in continuous ambulatory peritoneal dialysis. , 1993, The Journal of laboratory and clinical medicine.

[4]  R. Krediet,et al.  Interleukin-8 production by human peritoneal mesothelial cells in response to tumor necrosis factor-alpha, interleukin-1, and medium conditioned by macrophages cocultured with Staphylococcus epidermidis. , 1993, The Journal of infectious diseases.

[5]  B. Hylander,et al.  Interleukin-6 and interleukin-8 in dialysate and serum from patients on continuous ambulatory peritoneal dialysis. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  D. Struijk,et al.  Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD. , 1993, Kidney international.

[7]  J. Westwick,et al.  Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin-1 beta and tumor necrosis factor-alpha. , 1993, The American journal of pathology.

[8]  M. Davies,et al.  Cytokine Networks in Continuous Ambulatory Peritoneal Dialysis: Interactions of Resident Cells during Inflammation in the Peritoneal Cavity , 1993, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[9]  W. Luttmann,et al.  Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1β and TNFα , 1993 .

[10]  C. Dinarello.  Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during hemodialysis. , 1992, Kidney international. Supplement.

[11]  G. Camussi,et al.  Role of α1-proteinase inhibitor in restraining peritoneal inflammation in CAPD patients , 1992 .

[12]  M. Brockhaus,et al.  Plasma tumor necrosis factor soluble receptors in chronic renal failure. , 1992, Kidney international.

[13]  M. Brockhaus,et al.  Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. , 1992, The Journal of clinical investigation.

[14]  E. Bloemena,et al.  Interleukin-6 in CAPD patients without peritonitis: relationship to the intrinsic permeability of the peritoneal membrane. , 1992, Clinical nephrology.

[15]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[16]  Y. Bar-Khayim,et al.  Tumor necrosis factor (TNFα) binding protein: Interference in immunoassays of TNFα , 1991 .

[17]  E. Nilsson,et al.  On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. , 1991, The Journal of clinical investigation.

[18]  C. Nathan,et al.  Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. , 1991, The Journal of biological chemistry.

[19]  G. Adolf,et al.  A monoclonal antibody-based enzyme immunoassay for quantitation of human tumor necrosis factor binding protein I, a soluble fragment of the 60 kDa TNF receptor, in biological fluids. , 1991, Journal of immunological methods.

[20]  A. D. de Vos,et al.  Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. , 1991, Journal of immunological methods.

[21]  I. Bonta,et al.  Peritoneal macrophages from patients on continuous ambulatory peritoneal dialysis have an increased capability to release tumour necrosis factor during peritonitis. , 1991, Journal of clinical & laboratory immunology.

[22]  P. Vadas,et al.  Phospholipase A2--a mediator between proximal and distal effectors of inflammation. , 1991, Immunology today.

[23]  B. Echtenacher,et al.  Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. , 1990, Journal of immunology.

[24]  M. Slevin,et al.  Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. , 1990, Cytokine.

[25]  D. Wallach,et al.  Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. , 1990, The Journal of biological chemistry.

[26]  B. Descamps-Latscha,et al.  Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. , 1990, Kidney international.

[27]  W. Fiers,et al.  Intraperitoneal secretion of interleukin-6 during continuous ambulatory peritoneal dialysis. , 1990, Nephron.

[28]  A. Mantovani,et al.  Cytokines as communication signals between leukocytes and endothelial cells. , 1989, Immunology today.

[29]  M. Steinbeck,et al.  Neutrophil activation by recombinant cytokines. , 1989, Reviews of infectious diseases.

[30]  R. Smith,et al.  The active form of tumor necrosis factor is a trimer. , 1987, The Journal of biological chemistry.

[31]  H. Shepard,et al.  Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α , 1987, Nature.

[32]  P. Schollmeyer,et al.  Prostaglandin-mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis. , 1986, Kidney international.

[33]  R. Krediet,et al.  Peritoneal permeability to proteins in diabetic and non-diabetic continuous ambulatory peritoneal dialysis patients. , 1986, Nephron.

[34]  R. Krediet,et al.  CAPD peritonitis: a prospective randomized trial of oral versus intraperitoneal treatment with cephradine. , 1986, The Journal of antimicrobial chemotherapy.

[35]  H. Koren,et al.  Lipopolysaccharide (LPS) stimulates fresh human monocytes to lyse actinomycin D-treated WEHI-164 target cells via increased secretion of a monokine similar to tumor necrosis factor. , 1985, Journal of immunology.

[36]  B. Aggarwal,et al.  Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. , 1985, Science.

[37]  S. Vas,et al.  Microbiologic aspects of chronic ambulatory peritoneal dialysis. , 1983, Kidney international.

[38]  M. Peck,et al.  Role of prostaglandin-mediated vasodilatation in inflammation , 1977, Nature.